Joachim Ficker

List of Publications by Year
in descending order

117 papers	6,270 citations	117571 34 h-index	69214 77 g-index
170 all docs	170 docs citations	170 times ranked	4834 citing authors

#	Article	IF	Citations
1	A Randomized Study of Endobronchial Valves for Advanced Emphysema. New England Journal of Medicine, 2010, 363, 1233-1244.	13.9	704
2	Continuous Positive Airway Pressure Treatment Rapidly Improves Insulin Sensitivity in Patients with Obstructive Sleep Apnea Syndrome. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 156-162.	2.5	525
3	Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respiratory Medicine,the, 2013, 1, 199-209.	5.2	456
4	Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. European Respiratory Journal, 2012, 39, 1334-1342.	3.1	281
5	Sleep-disordered breathing and type 2 diabetes. Diabetes Research and Clinical Practice, 2008, 81, 2-12.	1.1	276
6	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 476-486.	5.2	254
7	Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1073-1082.	2.5	250
8	Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. European Respiratory Journal, 2003, 22, 251-257.	3.1	241
9	Radiological and clinical outcomes of using Chartisâ„¢ to plan endobronchial valve treatment. European Respiratory Journal, 2013, 41, 302-308.	3.1	221
10	The Effect of Continuous Positive Airway Pressure Treatment on Insulin Sensitivity in Patients with Obstructive Sleep Apnoea Syndrome and Type 2 Diabetes. Respiration, 2004, 71, 252-259.	1.2	198
11	Long-term efficacy and safety of Î±1 proteinase inhibitor treatment for emphysema caused by severe Î±1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respiratory Medicine,the, 2017, 5, 51-60.	5.2	151
12	Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. Pneumologie, 2011, 65, 39-59.	0.1	133
13	Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respiratory Medicine,the, 2016, 4, 185-193.	5.2	130
14	EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. British Journal of Cancer, 2013, 109, 1821-1828.	2.9	118
15	Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. European Respiratory Journal, 1998, 11, 14-19.	3.1	112
16	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. European Heart Journal, 2020, 41, 509-518.	1.0	106
17	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer, 2020, 20, 1185.	1.1	75
18	German S3ÂGuideline Nonrestorative Sleep/Sleep Disorders, chapter â€œSleep-Related Breathing Disorders in Adults,â€•short version. Somnologie, 2017, 21, 290-301.	0.9	72

#	Article	IF	Citations
19	Adiponectin in Patients with Obstructive Sleep Apnea Syndrome: Course and Physiological Relevance. Respiration, 2004, 71, 580-586.	1.2	57
20	Evaluation of an auto-CPAP device for treatment of obstructive sleep apnoea. Thorax, 1998, 53, 643-648.	2.7	55
21	A heated humidifier reduces upper airway dryness during continuous positive airway pressure therapy. Respiratory Medicine, 1999, 93, 21-26.	1.3	55
22	Inverse Correlation of Maturity and Antibacterial Activity in Human Dendritic Cells. Journal of Immunology, 2005, 174, 4203-4209.	0.4	52
23	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Cancers, 2020, 12, 2319.	1.7	52
24	Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. Journal of Internal Medicine, 2002, 252, 352-360.	2.7	49
25	Resistin levels in patients with obstructive sleep apnoea syndrome--the link to subclinical inflammation?. Medical Science Monitor, 2004, 10, CR510-5.	0.5	49
26	Evaluation of a Portable Recording Device (Somnocheck^{Â®}) for Use in Patients with Suspected Obstructive Sleep Apnoea. Respiration, 2001, 68, 307-312.	1.2	44
27	Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results. Lancet Respiratory Medicine,the, 2016, 4, e44-e45.	5.2	41
28	Initiation of CPAP Therapy for OSA: Does Prophylactic Humidification during CPAP Pressure Titration Improve Initial Patient Acceptance and Comfort?. Respiration, 2002, 69, 406-412.	1.2	40
29	Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies â€“ A Novel Stepwise Approach by Evaluation of Medication. PLoS ONE, 2016, 11, e0163408.	1.1	40
30	Effect of a patient engagement tool on positive airway pressure adherence: analysis of a German healthcare provider database. Sleep Medicine, 2018, 41, 20-26.	0.8	39
31	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS ONE, 2017, 12, e0177501.	1.1	37
32	Diagnosis and management of Î±1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Research, 2019, 5, 00171-2018.	1.1	36
33	Telemedicine-based proactive patient management during positive airway pressure therapy. Somnologie, 2017, 21, 121-127.	0.9	34
34	An auto-continuous positive airway pressure device controlled exclusively by the forced oscillation technique. European Respiratory Journal, 2000, 16, 914-920.	3.1	33
35	Obstructive sleep apnea (OSA) and clinical depressionâ€”prevalence in a sleep center. Sleep and Breathing, 2017, 21, 311-318.	0.9	33
36	Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer, 2016, 95, 35-38.	0.9	31

#	Article	IF	Citations
37	Adherence to Continuous Positive Airway Pressure Therapy for Obstructive Sleep Apnea: Impact of Patient Education after a Longer Treatment Period. Respiration, 2010, 80, 32-37.	1.2	29
38	Closure of persisting air leaks in patients with severe pleural empyema â€" use of endoscopic one-way endobronchial valveâ˜†. European Journal of Cardio-thoracic Surgery, 2011, 39, 401-403.	0.6	29
39	Auto-CPAP Therapy for Obstructive Sleep Apnea: Induction of Microarousals by Automatic Variations of CPAP Pressure?. Sleep, 2002, 25, 512-516.	0.6	28
40	Are Snoring Medical Students at Risk of Failing their Exams?. Sleep, 1999, 22, 205-209.	0.6	25
41	Detection of cardiovascular risk from a photoplethysmographic signal using a matching pursuit algorithm. Medical and Biological Engineering and Computing, 2016, 54, 1111-1121.	1.6	25
42	The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. International Journal of Cancer, 2014, 134, 2314-2321.	2.3	24
43	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clinical Medicine Insights: Oncology, 2020, 14, 117955492095135.	0.6	24
44	Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatology, The, 2022, 4, e351-e361.	2.2	24
45	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Translational Lung Cancer Research, 2021, 10, 3093-3105.	1.3	23
46	The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. International Journal of Oncology, 2015, 47, 963-970.	1.4	22
47	In vivo efficacy of heated and non-heated humidifiers during nasal continuous positive airway pressure (nCPAP)-therapy for obstructive sleep apnoea. Respiratory Medicine, 2000, 94, 364-368.	1.3	21
48	Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. International Journal of Cancer, 2013, 133, 1825-1831.	2.3	20
49	Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology and Therapeutics, 2017, 45, 19-33.	1.1	20
50	Comparison of PD-L1 mRNA Expression Measured with the CheckPoint TyperÂ® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 6771-6778.	0.5	20
51	Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis. Mycoses, 2022, 65, 747-752.	1.8	20
52	Reproducibility of a Standardized Titration Procedure for the Initiation of Continuous Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnoea. Respiration, 2001, 68, 145-150.	1.2	19
53	Stent Implantation for Superior Vena Cava Syndrome ofÂMalignant Cause. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2017, 189, 423-430.	0.7	18
54	Predictors of positive airway pressure therapy termination in the first year: analysis of big data from a German homecare provider. BMC Pulmonary Medicine, 2018, 18, 186.	0.8	17

#	Article	IF	Citations
55	Survival and quality of life after early discharge in low-risk pulmonary embolism. European Respiratory Journal, 2021, 57, 2002368.	3.1	17
56	Medical Treatment of COPD. Deutsches Ärzteblatt International, 2018, 155, 599-605.	0.6	17
57	In vivo Efficacy of Two Heated Humidifiers Used During CPAP-therapy for Obstructive Sleep Apnea Under Various Environmental Conditions. Sleep, 2001, 24, 435-440.	0.6	16
58	Insulin Resistance, Hyperleptinemia, and Obstructive Sleep Apnea in Launoisâ€Bensaude Syndrome. Obesity, 2002, 10, 625-632.	4.0	16
59	The use of overnight pulse wave analysis for recognition of cardiovascular risk factors and risk. Journal of Hypertension, 2014, 32, 276-285.	0.3	16
60	CAT score single item analysis in patients with COPD: Results from COSYCONET. Respiratory Medicine, 2019, 159, 105810.	1.3	16
61	Auto-CPAP therapy based on the forced oscillation technique. Auto-CPAP-Therapie auf der Basis der Oszilloresistometrie. Biomedizinische Technik, 2003, 48, 68-72.	0.9	13
62	Beyond the AHIâ€“pulse wave analysis during sleep for recognition of cardiovascular risk in sleep apnea patients. Journal of Sleep Research, 2021, 30, e13364.	1.7	13
63	Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. Pulmonary Pharmacology and Therapeutics, 2018, 49, 123-129.	1.1	12
64	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology,the, 2021, 8, e627-e636.	2.2	11
65	Detection of obstructive sleep apnea by analysis of phase angle using the forced oscillation signal. Respiration Physiology, 2000, 123, 87-99.	2.8	10
66	Sensitivity of a simplified forced oscillation technique for detection of upper airway obstruction. Respiration Physiology, 2001, 124, 243-249.	2.8	10
67	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice â€“ results from the ElderTac study. BMC Cancer, 2018, 18, 333.	1.1	10
68	Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort . Patient Preference and Adherence, 2019, Volume 13, 1711-1721.	0.8	10
69	Arousals: Aktueller Stand, Klinische Bedeutung und offene Fragen. Arousals: Actual Situation, Clinical Importance and Open Questions. Somnologie, 2001, 5, 24-45.	0.9	9
70	Vascular stiffness determined from a nocturnal digital pulse wave signal. Journal of Hypertension, 2016, 34, 2427-2433.	0.3	9
71	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	1.8	9
72	REM Sleep Imposes a Vascular Load in COPD Patients Independent of Sleep Apnea. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 565-572.	0.7	8

#	Article	IF	Citations
73	Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110123.	1.4	8
74	Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. Scientific Reports, 2022, 12, 1435.	1.6	8
75	Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial. Respiration, 2021, 100, 1174-1185.	1.2	6
76	Parameters of Overnight Pulse Wave under Treatment in Obstructive Sleep Apnea. Respiration, 2016, 92, 136-143.	1.2	5
77	Bridging Whole-Lung Lavage with Venovenous Extracorporeal Life Support for Pulmonary Alveolar Proteinosis. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1115-1117.	0.6	5
78	Low long-term mortality in patients with sleep apnoea and positive airway pressure therapy: analysis of aÂlarge German healthcare database. Somnologie, 2020, 24, 151-158.	0.9	5
79	Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. International Journal of COPD, 2021, Volume 16, 3189-3199.	0.9	5
80	Launois-Bensaude syndrome in a female with type 2 diabetes. Medical Science Monitor, 2003, 9, CS5-8.	0.5	5
81	Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS. Infection, 1998, 26, 368-374.	2.3	4
82	Humidification During Continuous Positive Airway Pressure Therapy. Chest, 2000, 117, 925.	0.4	4
83	Unilateral anhidrosis of the leg. Lancet, The, 2002, 360, 129.	6.3	4
84	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2021, 10, 4106-4119.	1.3	4
85	Arthropathy and cutaneous manifestations in a 28-year-old patient with cystic fibrosis. Monaldi Archives for Chest Disease, 2006, 65, 114-5.	0.3	3
86	CMR imaging for follow up of isolated cardiac sarcoidosis with extensive biventricular involvement. International Journal of Cardiology, 2016, 221, 777-779.	0.8	3
87	Improving Contrast Enhancement in Pulmonary CTA: The value of breathing maneuvers. European Journal of Radiology Open, 2020, 7, 100280.	0.7	3
88	Dual Bronchodilation With Once-Daily QVA149 Reduces Exacerbations, Improves Lung Function and Health Status Versus Glycopyrronium and Tiotropium in Severe-to-Very Severe COPD Patients: The SPARK Study. Chest, 2014, 145, 406A.	0.4	2
89	Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study. Chest, 2014, 145, 427A.	0.4	2
90	Influence of expression of estrogen (ERS-1) and progesterone (PGR) receptors on metastatic spread and outcome in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2011, 29, 7585-7585.	0.8	2

#	Article	IF	Citations
91	Cervical Emphysema in Boerhaave Syndrome. Deutsches Ärzteblatt International, 2019, 116, 211.	0.6	2
92	Das erste oszilloresistometrisch gesteuerte auto-CPAP-GerÃt (Somnosmart Â®)â€"Eine Therapie des lageabhÃngigen Schlafapnoe-Syndroms?. Somnologie, 1999, 3, 328-334.	0.9	1
93	Infected Mediastinal Bronchogenic Cyst in a 12 Year Old Girl. Thoracic and Cardiovascular Surgeon, 2012, 60, 239-241.	0.4	1
94	QVA149 versus glycopyrronium for COPD â€“ Authors' reply. Lancet Respiratory Medicine,the, 2013, 1, e23.	5.2	1
95	QVA149 Improves Lung Function and Reduces Exacerbations Compared With Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study. Chest, 2014, 145, 410A.	0.4	1
96	Dyspnea following intravenous drug use. Respiratory Medicine Case Reports, 2017, 20, 192-194.	0.2	1
97	Inhalable Insulin: The Breakthrough in Insulin Therapy?. Annals of Saudi Medicine, 2001, 21, 45-48.	0.5	1
98	Delays in the diagnosis and treatment of women with lung cancer: A systematic analysis.. Journal of Clinical Oncology, 2015, 33, e17740-e17740.	0.8	1
99	Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. , 2017, , .		1
100	Specialized Biopsychosocial Care in Inpatient Somatic Medicine Unitsâ€"A Pilot Study. Frontiers in Public Health, 2022, 10, 844874.	1.3	1
101	VALIDITÃ„T DES RESPIRATORISCHEN IMPEDANZSIGNALS HINSICHTLICH DER DETEKTION VON RESPIRATORISCHEN MUSTERN ZUR STEUERUNG EINER AUTO-CPAP-THERAPIE BEIM OBSTRUKTIVEN SCHLAFAPNOE-SY.. Biomedizinische Technik, 2000, 45, 442.	0.9	0
102	Bronchodilatateurs dans la BPCO : quoi de neuf ?. Revue Des Maladies Respiratoires Actualites, 2013, 5, 619-621.	0.0	0
103	Complete Cast of the Bronchial Tree. Deutsches Ärzteblatt International, 2019, 116, 318.	0.6	0
104	Gluteal abscess caused by Mycobacterium tuberculosis. Techniques in Coloproctology, 2020, 24, 1315-1316.	0.8	0
105	Editorial: Entwicklungen in der Bronchoskopie: Â"Bronchoskopie 2.0Â". Atemwegs- Und Lungenkrankheiten, 2013, 39, 157-158.	0.0	0
106	Bronchoskopische Lungenvolumenreduktion. Atemwegs- Und Lungenkrankheiten, 2013, 39, 224-237.	0.0	0
107	Prognostic value of immune response gene expression in early stage curatively resected NSCLC: Data from the JBR.10 trial.. Journal of Clinical Oncology, 2016, 34, 8528-8528.	0.8	0
108	Systematic analysis of self-reported comorbidities in the COSYCONET COPD cohort study by stepwise evaluation of medication. , 2016, , .		0

#	Article	IF	Citations
109	Targeted segmental volume reduction with vapor ablation in emphysema results in reduced RV and clinically meaningful improvement (CMI) in FEV1. , 2016, , .		0
110	Segmental lung volume reduction (LVR) with vapor better targets disease heterogeneity as compared to lobar LVR. , 2016, , .		0
111	Volume changes after segmental vapor ablation and associated improvements in FEV₁. , 2016, , .		0
112	STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results. , 2016, , .		0
113	Physician perspectives: barriers to diagnosing and treating severe AATD. , 2017, , .		0
114	Pulse wave analysis but not polysomnography recognizes sleep apnoea patients with increased cardiovascular risk. , 2017, , .		0
115	Association between change in positive airway pressure (PAP) mask type and therapy compliance. , 2017, , .		0
116	Late Breaking Abstract - Bronchoscopic Thermal Vapor Ablation (BTVA) Outcomes at 12 months in Emphysema Patients with Severe Hyperinflation, a STEP-UP RCT Subgroup Analysis. , 2017, , .		0
117	Disseminated manifestation of Kaposi's Sarcoma in newly diagnosed AIDS in an african female. Medical Science Monitor, 2001, 7, 1303-6.	0.5	0